Increased expression of miR-22 corresponds to the high-risk subtypes of myelodysplastic syndromes and lower OS rate
- 6 March 2020
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (7), 1763-1765
- https://doi.org/10.1080/10428194.2020.1734591
Abstract
(2020). Increased expression of miR-22 corresponds to the high-risk subtypes of myelodysplastic syndromes and lower OS rate. Leukemia & Lymphoma. Ahead of Print.This publication has 10 references indexed in Scilit:
- The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesBlood, 2019
- microRNA-22 promotes megakaryocyte differentiation through repression of its target, GFI1Blood Advances, 2019
- miR-22 suppresses DNA ligase III addiction in multiple myelomaLeukemia, 2018
- Consequences of mutant TET2 on clonality and subclonal hierarchyLeukemia, 2018
- The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene?PLoS Genetics, 2017
- The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid LeukemiaPLoS Genetics, 2016
- miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemiaNature Communications, 2016
- Circulating microRNA as Biomarkers in Hematological MalignanciesExperientia Supplementum, 2015
- TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhoodLeukemia Research, 2015
- The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and TransformationCell Stem Cell, 2013